Loading…
Shukra Pharmaceuticals (SHUKRAPHAR)₹82.05+0.58%Pharmaceuticals
Shukra Pharmaceuticals is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 110.9 against a peer median of 44.5, and ROCE of 36.9% against a peer median of 8.5%, and latest-quarter sales growth of 379.2% against a peer median of 22.3%. By market cap it is #7 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Aarti Drugs | 4,563 | 24.0 | 12.1 | 13.4 | 0.37 | 0.4 | 2,564 | 194 | 18.9 | −7.5 | vs SHUKRAPHAR |
| Zota Health Care | 4,410 | — | −8.0 | −15.1 | 0.39 | 0.1 | 539 | −74 | 54.2 | — | vs SHUKRAPHAR |
| Evonile Pharma | 4,343 | 44.5 | 16.0 | 11.7 | 0.00 | 0.0 | 353 | 93 | 18.1 | 14.3 | vs SHUKRAPHAR |
| RPG Life Sciences | 4,283 | 39.1 | 26.0 | 19.3 | 0.03 | 0.9 | 708 | 115 | 16.4 | −24.3 | vs SHUKRAPHAR |
| Gujarat Themis Biosyn | 4,138 | 88.5 | — | — | — | 0.2 | 165 | 47 | 22.3 | 22.5 | vs SHUKRAPHAR |
| Kwality Pharmaceuticals | 4,011 | 49.3 | 24.0 | 22.9 | 0.39 | 0.0 | 503 | 67 | 46.0 | 116.4 | vs SHUKRAPHAR |
| Shukra Pharmaceuticals | 3,618 | 110.9 | 36.9 | 28.9 | 0.06 | 0.0 | 57 | 22 | 379.2 | 1,191.1 | — |
| Unichem Laboratories | 3,584 | 11.7 | 4.0 | 3.2 | 0.18 | 0.0 | 2,200 | 253 | 20.0 | — | vs SHUKRAPHAR |
| Solara Active Pharma Sciences | 3,143 | 91.9 | 5.0 | −0.1 | 0.41 | 0.0 | 1,374 | −7 | 32.8 | — | vs SHUKRAPHAR |
| Ind-Swift Laboratories | 3,037 | 36.1 | 5.0 | 4.0 | 0.01 | 0.0 | 649 | 43 | 51.1 | 325.2 | vs SHUKRAPHAR |
| Hikal | 2,772 | — | 4.0 | 2.9 | 0.57 | 0.3 | 1,714 | −49 | 6.0 | — | vs SHUKRAPHAR |
| Peer median | 4,011 | 44.5 | 8.5 | 7.8 | 0.28 | 0.0 | 649 | 47 | 22.3 | 22.5 |
Listed companies closest to Shukra Pharmaceuticals in Pharmaceuticals include Aarti Drugs, Zota Health Care, Evonile Pharma, RPG Life Sciences, Gujarat Themis Biosyn, Kwality Pharmaceuticals, Unichem Laboratories, Solara Active Pharma Sciences.
Aarti Drugs, with a market cap of ₹4,563 Cr.
Shukra Pharmaceuticals trades at a P/E of 110.9; the median of its peer set is 44.5. A P/E above or below the median is a description, not a judgement on value.
Shukra Pharmaceuticals' return on capital employed is 36.9%, above the peer median of 8.5%.